UNSPSC 51202802: Ridaforolimus

This classification denotes an immunosuppressant with the molecular formula and that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48Z35KB15K., generally known as pomalidomide, which bears US NIH Compound Identifier 11520894. Most nations, for tariff and trade purposes, schedule ridaforolimus under HS 29349990 and SITC 51579. The term RIDAFOROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 1, 2010 List 63).

SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)C)O)OC)C)C)C)OC.

UNSPSC 51202802 Ridaforolimus, a Commodity code, does not map to active state and local procurement opportunities in the recent record. The two opportunities tagged to this code—a pharmaceutical warehouse piggyback contract awarded by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems—involve antibiotics and opioid-antagonist medications outside the scope of ridaforolimus, a targeted cancer therapy. The nominal code name and the actual work being procured diverge substantially, suggesting either a cataloging error in the state and local procurement system or the code's misapplication to these notices.

No recent open solicitations under this code are present in the source record. State and local buyers appear not to be currently soliciting ridaforolimus through routine procurement channels captured in recent notices, or the product category is not actively tagged with this UNSPSC code in practice. Until the code is applied consistently to relevant pharmaceutical oncology procurements, or recent opportunities directly tied to ridaforolimus supply emerge, this code presents minimal pursuit signal for business development purposes.